Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 12;400(10364):1712-1721.
doi: 10.1016/S0140-6736(22)01188-6. Epub 2022 Sep 26.

Current best practice for bladder cancer: a narrative review of diagnostics and treatments

Eva Compérat  1 , Mahul B Amin  2 , Richard Cathomas  3 , Ananya Choudhury  4 , Maria De Santis  5 , Ashish Kamat  6 , Arnulf Stenzl  7 , Harriet C Thoeny  8 , Johannes Alfred Witjes  9
Affiliations
Review

Current best practice for bladder cancer: a narrative review of diagnostics and treatments

Eva Compérat et al. Lancet. .

Abstract

This Seminar presents the current best practice for the diagnosis and management of bladder cancer. The scope of this Seminar ranges from current challenges in pathology, such as the evolving histological and molecular classification of disease, to advances in personalised medicine and novel imaging approaches. We discuss the current role of radiotherapy, surgical management of non-muscle-invasive and muscle-invasive disease, highlight the challenges of treatment of metastatic bladder cancer, and discuss the latest developments in systemic therapy. This Seminar is intended to provide physicians with knowledge of current issues in bladder cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AS receives consulting fees from Ipsen Pharma, Roche, and Janssen; is on the board for Synergo, Ferring, Astellas, and AstraZeneca; and receives research grants from Amgen, Ipsen Pharma, and Karl Storz. MBA receives consulting fees from Verily; and is on the board and has stock in LabCorp, Ibex Analytics, Precipio Diagnostics, Cell Max, and Core Diagnostics. MDS received consulting fees, honoraria, and support for attending meetings from AAA, Accord, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, Bristol Myers Squibb (BMS), Eisai, Ferring, Immunomedics, Gilead, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, and SeaGen; is on the board for Orion, Roche, AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, Eisai, Ferring, Immunomedics, Gilead, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Sandoz, Sanofi, and SeaGen; and contributed to the EAU prostate cancer guidelines, ESMO bladder cancer practice guidelines, and S3 Blasenkarzinom Leitlinie. AC received grants from Cancer Research UK, Prostate Cancer UK, Action for Bladder Cancer, National Institute for Health Research, and the Medical Research Council; honoraria from BMS, Roche, and Janssen; support for attending meetings from Elekta, BMS, Roche, Janssen, ASCO, and ESTRO; and is Editor-in-Chief for Clinical Oncology, Senior Editor for ASTRO International Journal of Radiation Oncology Biology and Physics, and is on the board for the National Institute of Clinical Excellence UK. RC receives consulting fees from Astellas, AstraZeneca, BMS, MSD, Roche, Janssen, Bayer, Gilead, Pfizer, and Merck; honoraria from Astellas and Janssen; support for attending meetings from AstraZeneca; and is a member of the SAKK board. AK received grants from Adolor, BMS, FKD Industries, Heat Biologics, Janssen, Merck, Photocure, Seattle Genetics, Taris, and SWOG; is on the board of and recieves consulting fees from Asieris, Astellas, Biological Dynamics, BMS, CG Oncology, H3 Biomedicine, Eisai, Engene, FerGene, Imagin Medical, Incyte DSMB, Janssen, Medac, Merck, Photocure, ProTara, Roche, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, US Biotest, and Urogen; has a joint patent for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) with UT MD Anderson Cancer Center; and is the President of IBCG. HCT is the Principal Investigator for SNF Nr 32003B_176229/1; and is on the board for and received honorarium from Guerbet. JAW received honararium from Nucleix. EC declares no competing interests.

MeSH terms